Article in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Yuncui YuClinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0000-0002-1559-9752
Wang CaoClinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0000-0003-3967-9244
Yue XiaoNational Health Development Research Center, National Health Commission, Beijing 100044, China.ORCID 0000-0001-5158-3267
Jing WeiClinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0009-0008-3757-5891
Huijie HuangDepartment of Allergy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0009-0006-9495-5853
Ang LiDepartment of Allergy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0009-0007-4939-7239
Mingyang ZhaoDepartment of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing 100069, China.ORCID 0009-0007-1338-0005
Lihua HuDepartment of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0009-0006-2160-5561
Chittawan PoonsiriHealth Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi 11000, Thailand.ORCID 0000-0003-2143-1662
Yot TeerawattananonHealth Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi 11000, Thailand.ORCID 0000-0003-2217-2930
Alec MortonSaw Swee Hock School of Public Health, National University of Singapore, Singapore 119077, Singapore.ORCID 0000-0003-3803-8517
Peng GuoClinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.ORCID 0009-0007-0726-0250
Funding
Belt and Road International Health Cooperation Project (2024-2025) NoneChina Medicine Education Association Clinical Medicine Evaluation Project 2023WSJSPGZXKT-23National "Belt and Road" Innovation Talent Exchange Foreign Expert Project DL2023001004L
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
asthmamedicine selection and prioritizationmulticriteria decision analysis (MCDA)omalizumab
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Assessing the Value of Omalizumab for Pediatric Asthma in China: A Multicriteria Decision Analysis. · full record | OpenQuestion